DLL4 and cancer: In previous studies, ABL001 has demonstrated anti-cancer effects with higher potency in several human cancer xenograft models compared to that shown by the VEGF-targeting antibody (bevacizumab-similar) and the DLL4-targeting monoclonal antibody alone [23,24].